Harness unparalleled healthcare data, advanced analytics, and cutting-edge technologies with our expertise to accelerate the development and commercialization of innovative medicines, enhancing patient lives.
Navigating MedTech's unique landscape: U.S. decision-making now rests with GPOs, IDNs, and payers, who demand solid value proof through rigorous outcomes analyses and pricing scrutiny.
Boost your innovation with IQVIA's expert team. Our comprehensive solutions integrate top-tier insights, technology, and expertise to maximize your asset's success in a competitive landscape.
Invest in healthcare with confidence. Stay ahead of pharma and medical device trends using real-time, high-quality data. Access market insights, historical sales, prescription trends, and emerging product information for informed, risk-reduced decisions.
Are 340B Discounts Directly Subsidizing Insured Patients or their Plans?
This study examines which types of patients are using 340B discount cards to better understand how 340B revenue is being used. The substantial amount of 340B card patients who had prescription drug coverage raises questions about the effectiveness of how 340B revenue is being used to support America's safety net. Click here to read the a brief summary of this study